\
&
Contact us
\
&
Contact us
Pick a topic from the menu to get started.
The information in this presentation is intended to inform companies about opportunities within the Horizon Europe and Digital Europe programmes and the support they can get when they intend to take part in a project under these two programmes.
DISCLAIMER - Always check the latest version of Commission documents for the most up-to-date information. NCP Flanders does not assume any liability or responsibility for the completeness, accuracy, or usefulness of the information included in this presentation.
Pick a topic from the menu to get started.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
